The purpose of this document is to provide guidance on information to present to the Food and Drug Administration (FDA) before a device to detect antibodies to B19 in serum or plasma specimens may be approved for marketing. This document is an adjunct to the CFR and the FDA 87-4214 Premarket Approval (PMA) Manuel.
Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)
If unable to submit comments online, please mail written comments to:
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All comments should be identified with the title of the guidance.